Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study [PDF]
Dermatology and Therapy, 2021 Introduction: Palmoplantar pustulosis (PPP) is a chronic, inflammatory skin disease, with high disease burden, that is often refractory to treatment. There is a high unmet clinical need for the treatment of patients with PPP.
Kristian Reich, Knut Schäkel
exaly +2 more sources
Lancet, The, 2023 Background: Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety of spesolimab for GPP flare prevention. Methods: This multicentre,
Milan Anadkat
exaly +2 more sources
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study [PDF]
Journal of the American Academy of Dermatology, 2023 BACKGROUND: Effisayil 1 was a randomized, placebo-controlled study of spesolimab, which is an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis flare.
Milan Anadkat
exaly +2 more sources
Related searches:
Spesolimab: A Novel Treatment for Pustular Psoriasis
Journal of Cutaneous Medicine and Surgery, 2020No abstract available Keywords: IL-36; acrodermatitis continua of hallopeau; generalized pustular psoriasis; localized pustular psoriasis; pustular psoriasis; spesolimab.
Kayadri Ratnarajah +3 more
openaire +2 more sources
Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis
Annals of PharmacotherapyObjective: This article reviews clinical trial data that assesses the safety, efficacy, and clinical application of spesolimab, an interleukin-36 (IL-36) blocker, for the treatment of generalized pustular psoriasis (GPP).
Steven R. Feldman +2 more
exaly +2 more sources
Journal of the American Academy of DermatologySupplementary Methods describe the study design, patient eligibility criteria, treatment regimen, and outcome measures used in this study. Statistical analyses for evaluating clinical efficacy and safety over 12 weeks are also detailed.
Panpan Liu, Yehong Kuang, Lihong Chen
exaly +2 more sources
Spesolimab Response in a Girl With Acrodermatitis Continua of Hallopeau
JAMA DermatologyThis case report summarizes the treatment of acrodermatitis continua of Hallopeau with spesolimab in a 9-year-old girl.
Youcong, Wang +4 more
openaire +2 more sources
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Rapid Resolution of Pediatric Acrodermatitis Continua of Hallopeau With Spesolimab
PediatricsAcrodermatitis continua of Hallopeau (ACH) is a sterile pustular psoriasis variant that is refractory to conventional therapies. The eruption typically develops following local trauma or infection, with other potential etiological factors including neural, inflammatory, and genetic origins.
Haiyang, He +4 more
openaire +2 more sources
Spesolimab Response in a Patient With Steroid-Resistant Sweet Syndrome
JAMA DermatologyThis case report describes a patient with Sweet syndrome whose condition improved with spesolimab after failure of high-dose corticosteroids.
Zhiyu, Pang +4 more
openaire +2 more sources